This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.
Part 2: Daratumumab Shows Greater PFS Benefit Early On in Multiple MyelomaJanuary 14th 2022
During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.
Part 2: Recommending Triplet and Quadruplet Therapies for Multiple MyelomaFebruary 11th 2022
During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.
Part 2: Using Depth of Response and MRD as Goals for Multiple MyelomaMay 2nd 2022
During a live virtual event, Douglas Sborov, MD, MS, discussed the most important goals for treatment and the use of minimal residual disease assessment for a patient with transplant-eligible multiple myeloma.
Multiple Myeloma Goals and Risk Factors for Triplet Vs Quadruplet TherapyJuly 13th 2022
During a live virtual event, Caitlin Costello, MD, discussed the rationale for choosing a triplet or quadruplet regimen for patients with transplant-eligible newly diagnosed multiple myeloma.
Using Frontline Quadruplet Therapy for Transplant-Eligible Multiple MyelomaSeptember 2nd 2022
During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.
The Role of Maintenance Daratumumab in Transplant-Eligible Multiple MyelomaOctober 5th 2022
During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.
Supportive Care for Maintenance in Transplant-Ineligible Multiple MyelomaFebruary 3rd 2023
During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.